NovaSignal secures $37 million in series C1. Funding will enable further commercial growth and the expansion of clinical trials.
NovaSignal Corp. announced today that its board of directors has appointed Mark R. Laret as an independent director, effective August 5, 2021. Mr. Laret is president and chief executive officer of UCSF Health.
More than 75% of the global burden of SCD occurs in sub-Saharan Africa, where an estimated 1.03 million children are afflicted. Learn more about how Dr. Nicole O’Brien and Nationwide Children’s Hospital is using TCD to help treat SCD in Africa!
With new live exam streaming capabilities, hospitals can expedite patient assessment and triage by quickly connecting patients with clinical specialists within the hospital or across the health system. Members of the clinical team can now remotely monitor vessel velocities and emboli count in real time, while automatic notifications on key events improve team coordination.
Transcranial Doppler (TCD) has been used to monitor the burden of cerebral microembolic signals (MESs) during atrial fibrillation (AF) ablation. MES burden is considered a surrogate marker for stroke risk and has never been reported during AF ablation with the novel pulsed field ablation (PFA) system.
The NovaSignal Platform empowers clinical teams with critical information about cerebral blood flow to guide diagnosis and improve patient outcomes. Designed to seamlessly integrate into existing clinical practice, the platform includes the NovaGuide 2 Intelligent Ultrasound which autonomously captures blood flow data to identify brain illnesses and disease, and NovaGuide View which provides secure, cloud-based access to dynamic exam data.